- Home
- RCS vs RXST Comparison
RCS vs RXST Comparison
Compare RCS & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCS
- RXST
- Stock Information
- Founded
- RCS 1994
- RXST 1997
- Country
- RCS United States
- RXST United States
- Employees
- RCS N/A
- RXST N/A
- Industry
- RCS Investment Managers
- RXST Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- RCS Finance
- RXST Health Care
- Exchange
- RCS Nasdaq
- RXST Nasdaq
- Market Cap
- RCS 334.5M
- RXST 347.8M
- IPO Year
- RCS N/A
- RXST 2021
- Fundamental
- Price
- RCS $7.33
- RXST $8.94
- Analyst Decision
- RCS
- RXST Hold
- Analyst Count
- RCS 0
- RXST 11
- Target Price
- RCS N/A
- RXST $11.80
- AVG Volume (30 Days)
- RCS 141.1K
- RXST 1.2M
- Earning Date
- RCS 01-01-0001
- RXST 11-06-2025
- Dividend Yield
- RCS 10.12%
- RXST N/A
- EPS Growth
- RCS N/A
- RXST N/A
- EPS
- RCS N/A
- RXST N/A
- Revenue
- RCS N/A
- RXST $147,059,000.00
- Revenue This Year
- RCS N/A
- RXST N/A
- Revenue Next Year
- RCS N/A
- RXST $6.71
- P/E Ratio
- RCS N/A
- RXST N/A
- Revenue Growth
- RCS N/A
- RXST 27.68
- 52 Week Low
- RCS $4.51
- RXST $6.32
- 52 Week High
- RCS $6.31
- RXST $57.53
- Technical
- Relative Strength Index (RSI)
- RCS 70.39
- RXST 52.97
- Support Level
- RCS $7.16
- RXST $8.29
- Resistance Level
- RCS $7.22
- RXST $9.19
- Average True Range (ATR)
- RCS 0.05
- RXST 0.49
- MACD
- RCS 0.01
- RXST 0.09
- Stochastic Oscillator
- RCS 97.80
- RXST 63.25
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.